Cargando…

TUXEDO: a phase I/II trial of cetuximab with chemoradiotherapy in muscle‐invasive bladder cancer

OBJECTIVE: To assess the feasibility and preliminary efficacy of adding cetuximab to standard chemoradiotherapy for muscle‐invasive bladder cancer. PATIENTS AND METHODS: TUXEDO was a prospective, single‐arm, open‐label, phase I/II trial conducted in six UK hospitals. Cetuximab was administered with...

Descripción completa

Detalles Bibliográficos
Autores principales:	James, Nicholas D., Liu, Wenyu, Pirrie, Sarah, Kaur, Baljit, Hendron, Carey, Ford, Daniel, Zarkar, Anjali, Viney, Richard, Southgate, Elizabeth, Desai, Amisha, Hussain, Syed A., Barber, Jim, Syndikus, Isabel, Malik, Zafar, Eswar, Chinnamani, Mangar, Stephen, Money‐Kyrle, Julian, Lydon, Anna, Van Der Voet, Johannes, James, Nicholas, Ford, Dan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087008/ https://www.ncbi.nlm.nih.gov/pubmed/35908256 http://dx.doi.org/10.1111/bju.15864

Ejemplares similares

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
por: James, Nicholas D., et al.
Publicado: (2022)

Science and technology: Tuxedo Park
por: Bissell, R E
Publicado: (2002)

Outcomes following external beam radiotherapy to the prostate and pelvic lymph nodes in addition to androgen deprivation therapy in non-metastatic prostate adenocarcinoma with regional lymph node involvement: a retrospective cohort study
por: Mohamad Roji, Akmal, et al.
Publicado: (2023)

Modernizing Oracle Tuxedo Applications with Python
por: Kalvans, Aivars
Publicado: (2021)

Usefulness and engagement with a guided workbook intervention (WorkPlan) to support work related goals among cancer survivors
por: Schumacher, Lauren, et al.
Publicado: (2017)

Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL)
por: Dearnaley, David, et al.
Publicado: (2019)

A Guided Workbook Intervention (WorkPlan) to Support Work-Related Goals Among Cancer Survivors: Protocol of a Feasibility Randomized Controlled Trial
por: Woods, Pernille Luxhøj, et al.
Publicado: (2016)

Feasibility randomised controlled trial of a guided workbook intervention to support work-related goals among cancer survivors in the UK
por: Grunfeld, Elizabeth A, et al.
Publicado: (2019)

First UK patient cohort treated with stereotactic ablative radiotherapy for primary kidney cancer
por: Zarkar, Anjali, et al.
Publicado: (2023)

Tuxedo Park: a Wall Street Tycoon and the secret palace of science that changed the course of World War II
por: Garvin, G
Publicado: (2002)

Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer
por: Hussain, S A, et al.
Publicado: (2004)

Two Cases of Pneumatosis Intestinalis during Cetuximab Therapy for Advanced Head and Neck Cancer
por: Miller, James A., et al.
Publicado: (2015)

Potential for elimination of folate and vitamin B(12) deficiency in India using vitamin-fortified tea: a preliminary study
por: Vora, Ravindra M, et al.
Publicado: (2021)

Randomized Noninferiority Trial of Reduced High-Dose Volume Versus Standard Volume Radiation Therapy for Muscle-Invasive Bladder Cancer: Results of the BC2001 Trial (CRUK/01/004)
por: Huddart, Robert A., et al.
Publicado: (2013)

Cetuximab produced from a goat mammary gland expression system is equally efficacious as innovator cetuximab in animal cancer models
por: Wang, Qian, et al.
Publicado: (2020)

Deep vein and artery thrombosis associated with cetuximab-based chemoradiotherapy
por: Gupta, Deepak, et al.
Publicado: (2011)

Cetuximab in Refractory Skin Cancer Treatment
por: Kalapurakal, Sini J, et al.
Publicado: (2012)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020)

p16, HPV, and Cetuximab: What Is the Evidence?
por: Bonner, James A., et al.
Publicado: (2017)

Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016)
por: Staffurth, John N., et al.
Publicado: (2021)

Dynamic prediction methods in the BC2001 clinical trial
por: Porta, Nuria, et al.
Publicado: (2015)

Transgenic goats producing an improved version of cetuximab in milk
por: Laible, Götz, et al.
Publicado: (2020)

Enhancement of Cetuximab-Induced Radiosensitization by JAK-1 Inhibition
por: Bonner, James A., et al.
Publicado: (2015)

Loss resilience for two-qubit state transmission using distributed phase sensitive amplification
por: Dailey, James M., et al.
Publicado: (2015)

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
por: Baker, J B, et al.
Publicado: (2011)

Cetuximab in the management of colorectal cancer
por: Lenz, Heinz-Josef
Publicado: (2007)

Molecular Shape, Architecture, and Size of P2X(4) Receptors Determined Using Fluorescence Resonance Energy Transfer and Electron Microscopy
por: Young, Mark T., et al.
Publicado: (2008)

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
por: Attard, Gerhardt, et al.
Publicado: (2022)

Quantification of mast cells in nonreactive and reactive lesions of gingiva: A comparative study using toluidine blue and immunohistochemical marker mast cell tryptase
por: Jain, Amisha, et al.
Publicado: (2021)

Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse
por: van As, N J, et al.
Publicado: (2008)

Mr. Bloomfield's orchard : the mysterious world of mushrooms, molds, and mycologists /
por: Money, Nicholas P.
Publicado: (2002)

Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
por: Wilkins, Anna, et al.
Publicado: (2015)

Impact of cetuximab conventional dosing on cetuximab-induced magnesium concentration under haemodialysis in head and neck cancer
por: Thariat, Juliette, et al.
Publicado: (2008)

The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent
por: Cheng, Yinwen, et al.
Publicado: (2021)

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer
por: Jonker, D J, et al.
Publicado: (2014)

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer
por: Klinghammer, Konrad, et al.
Publicado: (2020)

Combination of NTP with cetuximab inhibited invasion/migration of cetuximab-resistant OSCC cells: Involvement of NF-κB signaling
por: Chang, Jae Won, et al.
Publicado: (2015)

Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2022)

The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004)
por: Choudhury, Ananya, et al.
Publicado: (2017)

Cisplatin-Based Chemotherapy versus Cetuximab in Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer Treatment
por: Hu, Ming-Hung, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5m9hoj2vkobg661rpjvkp0087o